<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621359</url>
  </required_header>
  <id_info>
    <org_study_id>Quadruple therapy</org_study_id>
    <nct_id>NCT02621359</nct_id>
  </id_info>
  <brief_title>A Two Week Nitazoxanidebased Quadruple Regimen</brief_title>
  <official_title>A Two Week Nitazoxanidebased Quadruple Regimen for Helicobacter Pylori Therapy After Failure of Standard Triple Therapy: A Single Center Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with
      peptic ulcers, chronic gastritis, duodenitis, and stomach cancer.

      Therefore, the eradication of the pathogen is of critical importance to reduce H.
      pylori-related complications .

      However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has
      become more challenging. With a great decline in the eradication rate of standard triple
      therapy for Helicobacter pylori to below 70% in many countries.

      Treatment with triple therapy, which is the most frequently recommended, fails to eradicate
      H. pylori in approximately 20% of cases .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Designing a new rescue regimen that achieves greater than 85% eradication rate is an
      important target of current research.

      Unfortunately, the most frequently used &quot;rescue&quot; or &quot;salvage&quot; therapy is bismuth quadruple
      therapy consisting of a proton pump inhibitor (PPI), tetracycline, metronidazole, and bismuth
      [11]. This rescue therapy is inexpensive, and relatively effective with average eradication
      rate of 70% when used as second-line therapy. However, disadvantages of bismuth based
      quadruple therapy include the large daily number of pills (sometimes exceeding 18 pills),
      increased dosing frequency (four times daily), and frequent side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with eradicated helicobacter</measure>
    <time_frame>1 year</time_frame>
    <description>The total number of patients with eradicated helicobacter</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide 500 mg twice daily</description>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Alenia, nitclean, parazoxanide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin 500 mg once daily</description>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Tavanic, levoxin, venaxan.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycyclin</intervention_name>
    <description>Doxycyclin 100 mg twice daily</description>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Vibramycin, Doxymycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole 40 mg twice daily</description>
    <arm_group_label>Quadruple therapy</arm_group_label>
    <other_name>Omepak, Pepzole, Gasec, Risek.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with helicobacter infection.

          -  in whom the standard triple therapy (clarithromycin-based triple therapy) failed

        Exclusion Criteria:

          -  Patients under 18 or over 65 years of age.

          -  Those with co-existing serious illnesses such as liver cirrhosis, uremia and
             gastrointestinal malignancies

          -  pregnancy/lactation

          -  having contraindication or allergy to any of the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tropical medicine-Tanta university hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, lecturer</last_name>
    <phone>00201095159522</phone>
    <email>sherif_tropical@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tropical medicine dept.-Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam, lecturer</last_name>
      <phone>00201095159522</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>December 30, 2017</last_update_submitted>
  <last_update_submitted_qc>December 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Hepatology and Gastroenterology Dept., Tanta university, M.D., Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

